Literature DB >> 24389461

Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients.

Ana C Miranda Bastos1, Stefaan J Vandecasteele2, Paul M Tulkens3, Anne Spinewine4, Françoise Van Bambeke5.   

Abstract

Therapeutic drug monitoring of β-lactams can be useful for the optimization of therapy, especially when little reference data exist on actual pharmacokinetic profiles such as in patients undergoing haemodialysis. There is no reported validated method for temocillin assay in serum samples, and preliminary studies evidenced potential for interferences by acidic metabolites and co-administered drugs in patients with advanced kidney failure. This paper describes a fully validated method for the determination of temocillin in human serum, and its applicability in haemodialysis patients. Temocillin was extracted from human serum by a solid phase extraction methodology, and then assayed by reversed-phase HPLC with UV-detection. The method was validated according to the accuracy profile methodology, using total error to verify the trueness, precision and overall accuracy. It showed high specificity and precision and was accurate in the concentration range of 5-400 mg/L. LOD and LOQ were 1.2 and 5 mg/L, respectively. No interference with 30 co-administered drugs was evidenced. The method was successfully applied to clinical samples from haemodialysis patients, showing a high degree of dialysability of temocillin.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HPLC-UV; Haemodialysis; Temocillin; Therapeutic drug monitoring; Validation

Mesh:

Substances:

Year:  2013        PMID: 24389461     DOI: 10.1016/j.jpba.2013.12.002

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Temocillin.

Authors:  Kevin Alexandre; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

2.  Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial.

Authors:  Alicia Marín-Candón; Clara M Rosso-Fernández; Natalia Bustos de Godoy; Lorena López-Cerero; Belén Gutiérrez-Gutiérrez; Luis Eduardo López-Cortés; Lydia Barrera Pulido; Irene Borreguero Borreguero; María José León; Vicente Merino; Manuel Camean-Fernández; Pilar Retamar; Elena Salamanca; Alvaro Pascual; Jesús Rodriguez-Baño
Journal:  BMJ Open       Date:  2021-09-27       Impact factor: 2.692

Review 3.  Delivering precision antimicrobial therapy through closed-loop control systems.

Authors:  T M Rawson; D O'Hare; P Herrero; S Sharma; L S P Moore; E de Barra; J A Roberts; A C Gordon; W Hope; P Georgiou; A E G Cass; A H Holmes
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.